Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA® in prophylactic therapy

Haemophilia

Volumn 22, Issue 4, 2016, Pages 615-624

  Varadi, K ^a   Tangada, S ^b   Loeschberger, M ^a   Montsch, P ^a   Schrenk, G ^a   Ewenstein, B ^b   Turecek, P L ^a  

^a Baxalta Innovations   (Austria)

^b Baxalta   (United States)

Author keywords

FEIBA; haemophilia; inhibitors; prophylaxis; thrombin generation

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; PROTEIN C; PROTHROMBIN; THROMBIN;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFICACY; ENZYME SUBSTRATE COMPLEX; HEMOPHILIA A; HEMOSTASIS; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; THROMBIN GENERATION;

EID: 84979018655     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12873     Document Type: Article

References (39)

1. Bauer KA, Kass BL, ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood 1990; 76: 731–6.
2. Bauer KA, Kass BL, ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of factor X activation in humans. Blood 1989; 74: 2007–15.
3. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734–44.
4. Hellstern P, Beeck H, Fellhauer A, Fischer A, Faller-Stockl B. Measurement of factor VII and of activated factor VII in healthy individuals and in prothrombin complex concentrates. Thromb Res 1997; 86: 493–504.
5. Turecek PL, Schwarz HP. Factor eight inhibitor bypassing activity. In: Joseph Bertolini J, Goss N, Curling J eds. Production of Plasma Proteins for Therapeutic Use. Hoboken, NJ: John Wiley & Sons Inc., 2013: 49–63.
6. Turecek PL, Varadi K, Gritsch H et al. Factor Xa and prothrombin: mechanism of action of FEIBA. Vox Sang 1999; 77(Suppl. 1): 72–9.
7. Brufatto N, Ward A, Nesheim ME. Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost 2003; 1: 1258–63.
8. Baglia FA, Walsh PN. Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for platelet-mediated factor XI activation by thrombin. Biochemistry 1998; 37: 2271–81.
9. Wildgoose P, Kisiel W. Activation of human factor VII by factors IXa and Xa on human bladder carcinoma cells. Blood 1989; 73: 1888–95.
10. Liu L, Rodgers GM. Characterization of an inducible endothelial cell prothrombin activator. Blood 1996; 88: 2989–94.
11. Ofosu FA, Liu L, Freedman J. Control mechanisms in thrombin generation. Semin Thromb Hemost 1996; 22: 303–8.
12. Gailani D, Broze GJ, Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909–12.
13. Seligsohn U, Osterud B, Brown SF, Griffin JH, Rapaport SI. Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII. J Clin. Invest 1979; 64: 1056–65.
14. Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260–4.
15. Turecek PL, Varadi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia 2004; 10(Suppl. 2): 3–9.
16. Hoffman M, Monroe DM, III. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958–65.
17. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 2012; 10: 1478–85.
18. Antunes SV, Tangada S, Stasyshyn O et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014; 1: 65–72.
19. Ewing N, Escuriola-Ettingshausen C, Kreuz W. Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors. Haemophilia 2015; 21: 358–364.
20. Ogiwara K, Nogami K, Matsumoto T, Shima M. Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor. Int J Hematol 2014; 99: 577–87.
21. Varadi K, Siekmann J, Turecek PL, Schwarz HP, Marder VJ. Phospholipid-bound tissue factor modulates both thrombin generation and APC-mediated factor Va inactivation. Thromb Haemost 1999; 82: 1673–9.
22. Naser WL. Single incubation multilayer immune technique. J Immunol Methods 1990; 129: 151–7.
23. Turecek PL, Varadi K, Keil B et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003; 33: 16–22.
24. SAS Institute Inc. SAS/STAT 12.1 User's Guide. Cary, NC: SAS Institute Inc., 2012.
25. Váradi K, Negrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374–80.
26. Tardy-Poncet B, Piot M, Chapelle C, Berger C, Tardy B. Difference in TFPI levels between haemophilia A and B patients. Haemophilia 2011; 17: 312–3.
27. Duckers C, Simioni P, Spiezia L et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 2008; 112: 3615–23.
28. Elsinger F. Shortening of clotting times of hemophilia A plasma with inhibitors induced by activated factor IX concentrates (Fraction FEIBA). ICTH Task Force Meeting Clinical Use of FIX Concentrates, Paris, July, 20, 1975, (Oral Presentation) 1975.
29. Preston FE, Dinsdale RC, Sutcliffe DJ et al. Factor VIII inhibitor by-passing activity (FEIBA) in the management of patients with factor VIII inhibitors. Thromb Res 1977; 11: 643–51.
30. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36–40.
31. Repke D, Gemmell CH, Guha A et al. Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor. Proc Natl Acad Sci USA 1990; 87: 7623–7.
32. Broze GJ, Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992; 29: 159–69.
33. Roberts HR, Monroe DM, Oliver JA, Chang JY, Hoffman M. Newer concepts of blood coagulation. Haemophilia 1998; 4: 331–4.
34. Shenkman B, Einav Y, Livnat T et al. Rotation thromboelastometry analysis of clot formation and fibrinolysis in severethrombocytopenia: effect of fibrinogen, activated prothrombin complex concentrate, and thrombin- activatable fibrinolysis inhibitor. Int J Lab Hematol 2015; 37: 521–9.
35. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546–51.
36. Ettingshausen CE, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series. Haemophilia 2010; 16: 90–100.
37. Leissinger C, Gringeri A, Antmen B et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684–92.
38. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2008; 14: 39–43.
39. Eichinger S, Mannucci PM, Tradati F et al. Determinants of plasma factor VIIa levels in humans. Blood 1995; 86: 3021–5.